Source link : https://www.newshealth.biz/health-news/talazoparib-enzalutamide-improves-survival-in-metastatic-crpc/
(MedPage Today) — SAN FRANCISCO — Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged survival, new analyses from the TALAPRO-2 trial indicated. In… Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114203 Author : Publish date : 2025-02-13 18:12:27 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2025-02-13 18:12:27
Copyright for syndicated content belongs to the linked Source.